News & Investors
News
Lumicell Supports Stand Up To Cancer Dream Team for Early Detection of Gastric Cancer with Investigational Device and New Drug
Global Team Will Launch Gastric Cancer Prevention Clinical Trial. CAUTION – Investigational device and new drug. Limited by Federal (or United States) law to investigational use.
- Los Angeles
- January 8, 2026
Lumicell™ DVS Pivotal Trial Results Published in NEJM Evidence and to Be Presented at ASBrS Assess Safety and Effectiveness of System for Identifying Residual Breast Cancer During Lumpectomy
NEWTON, Mass., April 27, 2023—Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced that results of the Investigation of Novel Surgical Imaging for
Lumicell Direct Visualization System Premarket Approval Application Submitted to U.S. FDA for Intraoperative Breast Cancer Detection and Removal
Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced a Premarket Approval (PMA) application for its Lumicell™ Direct Visualization System (DVS) has
Lumicell Submits New Drug Application for LUMISIGHT™ Optical Imaging Agent to U.S. FDA for Intraoperative Breast Cancer Detection and Removal
Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced a New Drug Application (NDA) for its LUMISIGHT™ Optical Imaging Agent has been
Lumicell Appoints Brent Palmisano Chief Commercial Officer, Builds Commercial Team
Lumicell, Inc. today announced it is building a commercial team to prepare for market launch of the Lumicell Direct Visualization System (DVS) which includes its novel optical imaging agent LUMISIGHT,
Clinical Data on Lumicell’s Direct Visualization System to Be Presented at International Conference on Surgical Cancer Care
Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced that clinical data from a 234-patient, multi-center feasibility study of the Lumicell Direct
Lumicell Completes Enrollment in the INSITE Pivotal Trial for Intraoperative Breast Cancer Detection & Removal
In a significant milestone for breast cancer patients and advancement toward submission of its Lumicell Imaging System for regulatory approval, Lumicell has completed enrollment in their Investigation of Novel Surgical
Lumicell Granted Fast Track Designation Approval by the FDA for Breast Cancer Treatment
Lumicell, Inc., an innovation leader in image guided cancer surgery, today announced it has received Fast Track designation with rolling review from the FDA Center for Drug Evaluation and Research
Lumicell Announces Initiation of NIH/NCI Academic-Industry Study of its LUM Imaging System
R01 Award to fund multi-phase randomized study to expand clinical safety and efficacy data of the system in the detection of residual tumor in breast cancer patients receiving neoadjuvant therapies
Lumicell Initiates Pivotal Trial for Breast Cancer Surgical Guidance Solution
Success with In Vivo Examination of Cancerous Tissue via the Lumicell Imaging System During the Pivotal Trial will Propel the Technology Toward FDA Submission Newton, Mass., November 5, 2019 – Lumicell, Inc.,
Events
San Antonio Breast Cancer Symposium®,
December 10-14, 2024
Henry B. Gonzalez Convention Center
Investors
